Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

Weight loss jabs, known as GLP-1 receptor agonists, work by reducing food cravings. In October, the MHRA told health ...

Researchers at the, Riverside, backed by a substantial NIH grant, are pioneering a study on the unique immune responses to ...

Media maven Oprah Winfrey stirred controversy during a recent “The Oprah Podcast” episode with Yale University obesity medicine physician Dr.

Over-availability of food: Since cats do not need to hunt to eat when they are confined to the house, they sometimes eat just ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

There are steps you can take to help lower your risk of heart disease, but it can be expensive and require time, which is a ...

Recent findings indicate that widely used weight-loss medications might lead to muscle loss, including vital heart muscle, ...

We recently published a list of 10 Best Stocks to Buy and Hold For 2025. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other best stocks to buy and ...

The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.